For Genzyme, the wild ride continues

A virus, plant shutdown, FDA consent decree, Carl Icahn, and finally Sanofi-Aventis--what a ride it's been for Genzyme. But the rollercoaster has yet to come to a stop. Sanofi CEO Christopher Viehbacher says changes are coming to Genzyme as a result of the merger. "It wouldn't be credible to say there aren't going to be some cost savings along the way,'' he tells the Boston Globe. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.